Neoleukin Therapeutics, Inc.
1 day chart
Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.
Buy US stocks in Australia with $0 brokerage and trade NLTX today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.